Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.2811
+0.0521 (22.75%)
At close: Apr 25, 2025, 4:00 PM
0.2650
-0.0161 (-5.73%)
After-hours: Apr 25, 2025, 5:05 PM EDT
Cyclacel Pharmaceuticals Stock Forecast
CYCC's stock price has decreased by -87.78% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Cyclacel Pharmaceuticals stock has a target of 11, which predicts an increase of 3,813.20% from the current stock price of 0.28.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 3, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Cyclacel Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Roth MKM | Roth MKM | Strong Buy Maintains $21 → $11 | Strong Buy | Maintains | $21 → $11 | +3,813.20% | May 3, 2024 |
Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2023 |
Roth MKM | Roth MKM | Strong Buy Maintains $16 → $21 | Strong Buy | Maintains | $16 → $21 | +7,370.65% | Dec 19, 2023 |
Oppenheimer | Oppenheimer | Buy Maintains $120 | Buy | Maintains | $120 | +42,589.43% | May 25, 2023 |
Oppenheimer | Oppenheimer | Buy Maintains $150 → $120 | Buy | Maintains | $150 → $120 | +42,589.43% | Mar 7, 2023 |
Financial Forecast
Revenue This Year
102.00K
from 43.00K
Increased by 137.21%
Revenue Next Year
102.00K
from 102.00K
EPS This Year
-1.20
from -2.09
EPS Next Year
-1.14
from -1.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | 105,000 | 105,000 | 84.6M |
Avg | 102,000 | 102,000 | 82.2M |
Low | 98,000 | 98,000 | 79.0M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 144.2% | 2.9% | 82,852.0% |
Avg | 137.2% | - | 80,482.4% |
Low | 127.9% | -3.9% | 77,321.6% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -1.24 | -1.18 | 3.85 |
Avg | -1.20 | -1.14 | 3.74 |
Low | -1.16 | -1.10 | 3.60 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.